Toll Free: 1-888-928-9744

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL) - The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects - The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anaplastic Large Cell Lymphoma (ALCL) Overview 8 Therapeutics Development 9 Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 9 Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis 10 Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 11 Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes 12 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 16 Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes 17 Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 18 Ariad Pharmaceuticals, Inc. 18 AstraZeneca Plc 19 Bayer AG 20 Celon Pharma Sp. z o.o. 21 Pfizer Inc. 22 Sareum Holdings Plc 23 Seattle Genetics, Inc. 24 Teva Pharmaceutical Industries Limited 25 Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 AdIL-24 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AZD-3463 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 brentuximab vedotin - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 brigatinib - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CEP-28122 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CEP-37440 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 copanlisib hydrochloride - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 crizotinib - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 KRA-0008 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 SAR-3 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 SAR-4 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 SH-7129 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates 64 Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 95 Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products 96 Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 97 Featured News & Press Releases 97 Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 97 Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma 98 Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 99 Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 101 Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 103 Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 105 Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 106 Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 107 Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 107 Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 108 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2016 9 Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 18 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H1 2016 19 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H1 2016 20 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H1 2016 21 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H1 2016 22 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H1 2016 23 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H1 2016 24 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H1 2016 64 Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H1 2016 95 Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H1 2016 96



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify